
|Videos|March 23, 2021
Psychedelic Wellness
Author(s)Matt Stang
Early studies find psilocybin shows promise for some psychiatric disorders...
Advertisement
With numerous studies in stage 3 trials, the opportunities to leverage psilocybin for clinical care is likely to expand in the next few years. Matt Stang shares his excitement for the future of this agent as means to help more patients.
To learn more on psilocybin and earn CME credit, see
Mr Stang is the founder of
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder
2
FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults
3
Psychiatric Pharmacogenomics: An Overview
4
Phase 2 Analysis of ML-004 for Autism Spectrum Disorder Fails to Meet Endpoint
5











